Jeffrey L Wolf
Overview
Explore the profile of Jeffrey L Wolf including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
633
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Galarza Fortuna G, Banerjee R, Savid-Frontera C, Song J, Moran-Segura C, Nguyen J, et al.
Blood Cancer J
. 2024 Oct;
14(1):180.
PMID: 39414769
We report 14 cases of immune effector cell (IEC)-associated enterocolitis following chimeric antigen receptor T-cell (CAR-T) therapy in multiple myeloma, with a 1.2% incidence overall (0.2% for idecabtagene vicleucel and...
2.
Reyes K, Liu Y, Huang C, Banerjee R, Martin T, Wong S, et al.
Blood Adv
. 2024 Mar;
8(9):2207-2216.
PMID: 38429087
For patients with relapsed/refractory multiple myeloma with a relapse after B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell therapy (CAR-T), optimal salvage treatment strategies remain unclear. BCMA-directed CAR-T and bispecific...
3.
Duvalyan E, Shah N, Lo M, Martin 3rd T, Wolf J, Chung A, et al.
Leuk Lymphoma
. 2023 Aug;
64(11):1888-1891.
PMID: 37599633
No abstract available.
4.
Chung A, Banbury B, Vignali M, Huang C, Sireesha Asoori , Johnson R, et al.
Br J Haematol
. 2022 Aug;
199(4):520-528.
PMID: 36041779
We investigated antibody and coronavirus disease 2019 (COVID-19)-specific T-cell mediated responses via ultra-deep immunosequencing of the T-cell receptor (TCR) repertoire in patients with plasma cell dyscrasias (PCD). We identified 364...
5.
Banerjee R, Lazar A, Dunn L, Knoche J, Lo M, Arora S, et al.
EJHaem
. 2022 Jul;
2(2):276-279.
PMID: 35845271
Multiple myeloma patients undergoing autologous stem cell transplantation (ASCT) may receive benzodiazepine or zolpidem-class (B/Z) medications despite their risks in older patients. Of 205 myeloma patients (36% aged 65+) who...
6.
Ferguson I, Patino-Escobar B, Tuomivaara S, Lin Y, Nix M, Leung K, et al.
Nat Commun
. 2022 Jul;
13(1):4121.
PMID: 35840578
The myeloma surface proteome (surfaceome) determines tumor interaction with the microenvironment and serves as an emerging arena for therapeutic development. Here, we use glycoprotein capture proteomics to define the myeloma...
7.
Dinh A, Wong S, Martin T, Wolf J, Webber A
Clin Transplant
. 2021 Nov;
36(3):e14541.
PMID: 34797567
Transplant centers have historically been reluctant to proceed with kidney transplantation in individuals with plasma cell dyscrasias (PCDs) due to concern for high rates of PCD recurrence and PCD-related mortality....
8.
Sun H, Martin T, Marra J, Kong D, Keats J, Mace S, et al.
J Immunother Cancer
. 2021 Jul;
9(7).
PMID: 34272304
Background: Phase IIb clinical trial with isatuximab (Isa)-lenalidomide (Len)-dexamethasone (Dex) showed an improved progression-free survival (PFS) in patients with relapsed or refractory multiple myeloma (RRMM), but the efficacy varied by...
9.
Banerjee R, Marsal J, Huang C, Lo M, Thiruvengadam S, Kennedy V, et al.
Transplant Cell Ther
. 2021 Apr;
27(6):477.e1-477.e7.
PMID: 33831353
Preemptive administration of tocilizumab (toci) to manage cytokine release syndrome (CRS) after chimeric antigen receptor T cell (CAR-T) therapy may reduce rates of serious CRS but conversely may worsen neurotoxicity...
10.
Martin T, Shah N, Richter J, Vesole D, Wong S, Huang C, et al.
Cancer
. 2021 Mar;
127(11):1816-1826.
PMID: 33735504
Background: Isatuximab (Isa), an anti-CD38 monoclonal antibody, and carfilzomib (K), a next-generation proteasome inhibitor (PI), both have potent single-agent activity in relapsed and refractory multiple myeloma (RRMM). Methods: This phase...